FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016993385> ?p ?o ?g. }

• W2016993385 endingPage "6395" @default.
• W2016993385 startingPage "6395" @default.
• W2016993385 abstract "To investigate the efficacy and safety of n-3 polyunsaturated fatty acids (PUFA) from seal oils for patients with nonalcoholic fatty liver disease (NAFLD) associated with hyperlipidemia.One hundred and forty-four patients with NAFLD associated with hyperlipidemia were included in the 24-wk, randomized, controlled trial. The patients were randomized into two groups. Group A (n=72) received recommended diet and 2 g n-3 PUFA from seal oils, three times a day. Group B (n=72) received recommended diet and 2 g placebo, three times a day. Primary endpoints were fatty liver assessed by symptom scores, liver alanine aminotransferase (ALT) and serum lipid levels after 8, 12, 16, and 24 wk. Hepatic fat infiltration was detected by ultrasonography at weeks 12 and 24 after treatment.A total of 134 patients (66 in group A, 68 in group B) were included in the study except for 10 patients who were excluded from the study. After 24 wk of treatment, no change was observed in body weight, fasting blood glucose (FBG), renal function and blood cells of these patients. Total symptom scores, ALT and triglyceride (TG) levels decreased more significantly in group A than in group B (P<0.05). As expected, there was a tendency toward improvement in aspartate aminotransferase (AST), gamma-glutamyltranspeptidase (GGT), and total cholesterol (TCHO) and high-density lipoprotein (HDL) cholesterol levels (P<0.05) after administration in the two groups. However, no significant differences were found between the two groups. The values of low-density lipoprotein (LDL) were significantly improved in group A (P<0.05), but no significant change was found in group B at different time points and after a 24-wk treatment. After treatment, complete fatty liver regression was observed in 19.70% (13/66) of the patients, and an overall reduction was found in 53.03% (35/66) of the patients in group A. In contrast, in group B, only five patients (7.35%, 5/68) achieved complete fatty liver regression (P=0.04), whereas 24 patients (35.29%, 24/68) had a certain improvement in fatty liver (P=0.04). No serious adverse events occurred in all the patients who completed the treatment.Our results indicate that n-3 PUFA from seal oils is safe and efficacious for patients with NAFLD associated with hyperlipidemia and can improve their total symptom scores, ALT, serum lipid levels and normalization of ultrasonographic evidence. Further study is needed to confirm these results." @default.
• W2016993385 created "2016-06-24" @default.
• W2016993385 creator A5031116979 @default.
• W2016993385 creator A5036622608 @default.
• W2016993385 creator A5055072492 @default.
• W2016993385 creator A5055795122 @default.
• W2016993385 creator A5062584174 @default.
• W2016993385 date "2008-01-01" @default.
• W2016993385 modified "2023-10-16" @default.
• W2016993385 title "Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia" @default.
• W2016993385 cites W1534724641 @default.
• W2016993385 cites W1972003125 @default.
• W2016993385 cites W1975961609 @default.
• W2016993385 cites W1986639152 @default.
• W2016993385 cites W1989620365 @default.
• W2016993385 cites W1990298810 @default.
• W2016993385 cites W1994210784 @default.
• W2016993385 cites W2006162642 @default.
• W2016993385 cites W2008162733 @default.
• W2016993385 cites W2012257654 @default.
• W2016993385 cites W2025765870 @default.
• W2016993385 cites W2032980112 @default.
• W2016993385 cites W2034619043 @default.
• W2016993385 cites W2040109162 @default.
• W2016993385 cites W2046360039 @default.
• W2016993385 cites W2052981488 @default.
• W2016993385 cites W2062663604 @default.
• W2016993385 cites W2064132909 @default.
• W2016993385 cites W2066047347 @default.
• W2016993385 cites W2068075000 @default.
• W2016993385 cites W2074985929 @default.
• W2016993385 cites W2079038777 @default.
• W2016993385 cites W2092356581 @default.
• W2016993385 cites W2093308509 @default.
• W2016993385 cites W2093824918 @default.
• W2016993385 cites W2094826897 @default.
• W2016993385 cites W2096695647 @default.
• W2016993385 cites W2102656403 @default.
• W2016993385 cites W2110319339 @default.
• W2016993385 cites W2114906642 @default.
• W2016993385 cites W2144178804 @default.
• W2016993385 cites W2144591738 @default.
• W2016993385 cites W2152623405 @default.
• W2016993385 cites W2158718494 @default.
• W2016993385 cites W2312561541 @default.
• W2016993385 cites W4234643136 @default.
• W2016993385 doi "https://doi.org/10.3748/wjg.14.6395" @default.
• W2016993385 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2766124" @default.
• W2016993385 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19009658" @default.
• W2016993385 hasPublicationYear "2008" @default.
• W2016993385 type Work @default.
• W2016993385 sameAs 2016993385 @default.
• W2016993385 citedByCount "166" @default.
• W2016993385 countsByYear W20169933852012 @default.
• W2016993385 countsByYear W20169933852013 @default.
• W2016993385 countsByYear W20169933852014 @default.
• W2016993385 countsByYear W20169933852015 @default.
• W2016993385 countsByYear W20169933852016 @default.
• W2016993385 countsByYear W20169933852017 @default.
• W2016993385 countsByYear W20169933852018 @default.
• W2016993385 countsByYear W20169933852019 @default.
• W2016993385 countsByYear W20169933852020 @default.
• W2016993385 countsByYear W20169933852021 @default.
• W2016993385 countsByYear W20169933852022 @default.
• W2016993385 countsByYear W20169933852023 @default.
• W2016993385 crossrefType "journal-article" @default.
• W2016993385 hasAuthorship W2016993385A5031116979 @default.
• W2016993385 hasAuthorship W2016993385A5036622608 @default.
• W2016993385 hasAuthorship W2016993385A5055072492 @default.
• W2016993385 hasAuthorship W2016993385A5055795122 @default.
• W2016993385 hasAuthorship W2016993385A5062584174 @default.
• W2016993385 hasBestOaLocation W20169933851 @default.
• W2016993385 hasConcept C126322002 @default.
• W2016993385 hasConcept C134018914 @default.
• W2016993385 hasConcept C139572402 @default.
• W2016993385 hasConcept C181199279 @default.
• W2016993385 hasConcept C19038510 @default.
• W2016993385 hasConcept C2776954865 @default.
• W2016993385 hasConcept C2778163477 @default.
• W2016993385 hasConcept C2778772119 @default.
• W2016993385 hasConcept C2778913445 @default.
• W2016993385 hasConcept C2779091943 @default.
• W2016993385 hasConcept C2779134260 @default.
• W2016993385 hasConcept C2781278919 @default.
• W2016993385 hasConcept C2992208098 @default.
• W2016993385 hasConcept C543025807 @default.
• W2016993385 hasConcept C55493867 @default.
• W2016993385 hasConcept C555293320 @default.
• W2016993385 hasConcept C71924100 @default.
• W2016993385 hasConcept C86803240 @default.
• W2016993385 hasConcept C90924648 @default.
• W2016993385 hasConceptScore W2016993385C126322002 @default.
• W2016993385 hasConceptScore W2016993385C134018914 @default.
• W2016993385 hasConceptScore W2016993385C139572402 @default.
• W2016993385 hasConceptScore W2016993385C181199279 @default.
• W2016993385 hasConceptScore W2016993385C19038510 @default.
• W2016993385 hasConceptScore W2016993385C2776954865 @default.
• W2016993385 hasConceptScore W2016993385C2778163477 @default.

• next